GLMD

Recent Business Developments: Galmed Pharmaceuticals has adopted a digital asset management strategy, potentially allocating up to 50% of its cash reserves (approximately $10 million) for crypto investments, overseen by a newly formed Crypto Committee.

Termination of Licensing Agreement: The company terminated a licensing agreement with Entomus s.r.o. regarding a Self-Emulsifying Drug Delivery System (SEDDS), opting instead to invest in a new UK-based company for its development, with Galmed planning to acquire up to 20% of its share capital.

Financial Performance Overview: As of June 30, 2025, Galmed reported a net loss of approximately $2.5 million, an increase from the previous year, while cash and equivalents rose to about $20.7 million compared to $15.4 million at the end of 2024.

Focus on Product Development: Galmed continues to focus on advancing Aramchol for liver disease treatment and exploring opportunities in cardiometabolic diseases and other innovative product candidates aligned with its expertise in drug development.

Share Capital Increase: Galmed Pharmaceuticals approved an amendment to increase its authorized share capital from 50 million to 900 million ordinary shares during a Special General Meeting on August 15, 2025.

Digital Asset Management Strategy: The company plans to invest up to $10 million, about 50% of its cash reserves, into a digital asset management strategy that includes options like staking and yield-generating protocols.

Engagement with Tectona Ltd.: Galmed is engaging Tectona Ltd., a crypto treasury management service provider, to assist in implementing its digital asset strategy and ensure best practices in security and compliance.

Objective of Treasury Policy: The new treasury investment policy aims to diversify Galmed's balance sheet, enhance capital efficiency, and leverage blockchain opportunities while maintaining liquidity for operational needs.

Palo Alto Networks Financial Performance: Palo Alto Networks, Inc. reported strong financial results for Q4 of fiscal 2025, with revenue increasing by 16% year-over-year to $2.54 billion and adjusted earnings per share at 95 cents, surpassing analyst expectations.

Stock Movement: Following the positive earnings report, shares of Palo Alto Networks rose by 6.6% in pre-market trading, reaching $187.81.

Other Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, including Laser Photonics Corp, which surged 65.5%, and Color Star Technology Co Ltd, which gained 60.3%.

Declining Stocks: Conversely, some stocks saw declines, such as ALX Oncology Holdings Inc, which fell 19%, and Soligenix, Inc., which dipped 16.7% after previous gains.